This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brier, M. E.
Right arrow Articles by Jungbluth, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brier, M. E.
Right arrow Articles by Jungbluth, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 2775-2780, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2775-2780.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction

Michael E. Brier,1,2* Dennis J. Stalker,3 George R. Aronoff,1 Donald H. Batts,3 Kristi K. Ryan,3 Margaret O'Grady,1 Nancy K. Hopkins,3 and Gail L. Jungbluth3

University of Louisville,1 Department of Veterans Affairs, Louisville, Kentucky,2 Pharmacia and Upjohn Company, Kalamazoo, Michigan3

Received 30 September 2002/ Returned for modification 20 February 2003/ Accepted 30 May 2003

Linezolid is a member of a new, unique class of synthetic antibacterial agents called oxazolidinones that are effective against gram-positive bacteria, including vancomycin-resistant organisms. We tested the hypothesis that the linezolid clearance would not be altered in subjects with renal dysfunction. Twenty-four subjects with renal function that ranged from normal to severe chronic impairment were enrolled, including patients with end-stage renal disease who were maintained on hemodialysis. Hemodialysis subjects were studied while they were both on and off dialysis. Linezolid was administered as a single oral 600-mg dose, and plasma and urine samples were assayed for linezolid and metabolites for 48 h for all subjects and for up to 96 h for those subjects with impaired renal function not on dialysis. The total apparent oral clearance of linezolid did not change with renal function and ranged from 92.5 to 109.6 ml/min for subjects not requiring dialysis. For subjects on dialysis, the total apparent oral clearance increased from 76.6 ml/min on their off-dialysis day to 130.0 ml/min on their on-dialysis day. Approximately one-third of the dose was removed by dialysis. However, those subjects with severe renal insufficiency (creatinine clearance, <40 ml/min) and those with end-stage renal disease maintained on hemodialysis had higher concentrations of both metabolites. We conclude that no adjustment of the linezolid dosage is needed in subjects with renal dysfunction or subjects on hemodialysis.

* Corresponding author. Mailing address: University of Louisville, 615 South Preston St., Louisville, KY 40202. Phone: (502) 852-0246. Fax: (502) 852-7643. E-mail: mbrier{at}louisville.edu.

Antimicrobial Agents and Chemotherapy, September 2003, p. 2775-2780, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2775-2780.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Abe, S., Chiba, K., Cirincione, B., Grasela, T. H., Ito, K., Suwa, T. (2009). Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients. J Clin Pharmacol 49: 1071-1078 [Abstract] [Full Text]  
  • Ponticelli, C. (2008). New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients. Nephrol Dial Transplant 23: 27-32 [Full Text]  
  • Plock, N., Buerger, C., Joukhadar, C., Kljucar, S., Kloft, C. (2007). Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients. Drug Metab. Dispos. 35: 1816-1823 [Abstract] [Full Text]  
  • Soriano, A., Ortega, M., Garcia, S., Penarroja, G., Bove, A., Marcos, M., Martinez, J. C., Martinez, J. A., Mensa, J. (2007). Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid. Antimicrob. Agents Chemother. 51: 2559-2563 [Abstract] [Full Text]  
  • Myrianthefs, P., Markantonis, S. L., Vlachos, K., Anagnostaki, M., Boutzouka, E., Panidis, D., Baltopoulos, G. (2006). Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients. Antimicrob. Agents Chemother. 50: 3971-3976 [Abstract] [Full Text]  
  • Fiaccadori, E., Maggiore, U., Rotelli, C., Giacosa, R., Parenti, E., Picetti, E., Manini, P., Andreoli, R., Cabassi, A. (2006). Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 21: 1402-1406 [Abstract] [Full Text]  
  • Meyer, B., Kornek, G. V., Nikfardjam, M., Karth, G. D., Heinz, G., Locker, G. J., Jaeger, W., Thalhammer, F. (2005). Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 56: 172-179 [Abstract] [Full Text]  
  • Schriever, C., Zeitz-Colaizzi, L., Quinn, A., Schriever, A. E., Cannon, J. P. (2005). Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit. Journal of Pharmacy Practice 18: 100-108 [Abstract]  
  • Whitehouse, T., Cepeda, J. A., Shulman, R., Aarons, L., Nalda-Molina, R., Tobin, C., MacGowan, A., Shaw, S., Kibbler, C., Singer, M., Wilson, A. P. R. (2005). Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 55: 333-340 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»